Evidence map›Paper›PMID 33122723›Full record

ArticleScientific reports2020

SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer.

Joshua T Burgess, Emma Bolderson, Mark N Adams, Pascal H G Duijf, Shu-Dong Zhang, Steven G Gray, Gavin Wright, Derek J Richard, Kenneth J O'Byrne

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Joshua T BurgessCancer and Ageing Research Program, Centre for Genomics and Personalised Health at the Translational Research Institute (TRI), Queensland University of Technology, 37 Kent Street Woolloongabba, Brisbane, 4102, Australia. j6.burgess@qut.edu.au.
Emma BoldersonCancer and Ageing Research Program, Centre for Genomics and Personalised Health at the Translational Research Institute (TRI), Queensland University of Technology, 37 Kent Street Woolloongabba, Brisbane, 4102, Australia. emma.bolderson@qut.edu.au.
Mark N AdamsCancer and Ageing Research Program, Centre for Genomics and Personalised Health at the Translational Research Institute (TRI), Queensland University of Technology, 37 Kent Street Woolloongabba, Brisbane, 4102, Australia.
Pascal H G DuijfCancer and Ageing Research Program, Centre for Genomics and Personalised Health at the Translational Research Institute (TRI), Queensland University of Technology, 37 Kent Street Woolloongabba, Brisbane, 4102, Australia.
Shu-Dong ZhangNorthern Ireland Centre for Stratified Medicine, University of Ulster, C-TRIC Building, Altnagelvin Hospital Campus, Glenshane Road, Londonderry, BT47 6SB, UK.
Steven G GrayThoracic Oncology Research Group, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland.
Gavin WrightDepartment of Surgery, St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia.
Derek J RichardCancer and Ageing Research Program, Centre for Genomics and Personalised Health at the Translational Research Institute (TRI), Queensland University of Technology, 37 Kent Street Woolloongabba, Brisbane, 4102, Australia.
Kenneth J O'ByrneCancer and Ageing Research Program, Centre for Genomics and Personalised Health at the Translational Research Institute (TRI), Queensland University of Technology, 37 Kent Street Woolloongabba, Brisbane, 4102, Australia. ken.obyrne@qut.edu.au.
Queensland University of Technology · AUPrincess Alexandra Hospital · AUQueen's University Belfast · GBThe University of Melbourne · AUTranslational Research Institute · AUTrinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SASH1 (SAM and SH3 domain-containing protein 1) is a tumor suppressor protein that has roles in key cellular processes including apoptosis and cellular proliferation. As these cellular processes are frequently disrupted in human tumours and little is known about the role of SASH1 in the pathogenesis of the disease, we analysed the prognostic value of SASH1 in non-small cell lung cancers using publicly available datasets. Here, we show that low SASH1 mRNA expression is associated with poor survival in adenocarcinoma. Supporting this, modulation of SASH1 levels in a panel of lung cancer cell lines mediated changes in cellular proliferation and sensitivity to cisplatin. The treatment of lung cancer cells with chloropyramine, a compound that increases SASH1 protein concentrations, reduced cellular proliferation and increased sensitivity to cisplatin in a SASH1-dependent manner. In summary, compounds that increase SASH1 protein levels could represent a novel approach to treat NSCLC and warrant further study.

Indexed as

A549 CellsApoptosisCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCisplatinGene Expression Regulation, NeoplasticHumansLung NeoplasmsPrognosisRNA, MessengerTumor Suppressor ProteinsCisplatinRNA, MessengerSASH1 protein, humanTumor Suppressor Proteins

Identifiers

PMID33122723
PMCPMC7596716
OpenAlexW3097551245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.